Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Roche: OAK Data Differentiates Tecentriq In Second-Line Lung Cancer

Executive Summary

ESMO data suggest that patients with no expression of PD-L1 who took Tecentriq were able to generate an immune response, a result Genentech believes reflects the particular mechanism of action compared to PD-1 inhibitors like Opdivo and Keytruda.

Advertisement

Related Content

PD-1 Deep Dive: Lung Cancer Market Braced For Change
Keeping Track: Oncology Approvals And Responses To Complete Response Letters
Roche Boasts Of Tecentriq's Broad Potential In 3Q Earnings Update
Roche Raises IO Credentials On Tecentriq Lung Cancer Data

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register